<SEC-DOCUMENT>0001125345-17-000093.txt : 20170831
<SEC-HEADER>0001125345-17-000093.hdr.sgml : 20170831
<ACCEPTANCE-DATETIME>20170831170547
ACCESSION NUMBER:		0001125345-17-000093
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170829
ITEM INFORMATION:		Termination of a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170831
DATE AS OF CHANGE:		20170831

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		171063895

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form_8-kxjanssenterminatio.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s96E80AE6B25778448628395B65804471"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:144%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;WASHINGTON, D.C. 20549</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________</font></div><div style="line-height:144%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:144%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Pursuant to Section 13 or 15(d) of the</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of report (Date of earliest event reported):&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">August 29, 2017</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;(Exact Name of Registrant as Specified in Charter)</font></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:30%;"></td><td style="width:35%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-36112</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">06-1591613</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or Other Jurisdiction</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of Incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:64%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9704 Medical Center Drive,</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Rockville, Maryland</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">20850</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(301) 251-5172</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Not applicable</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160; ] Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;[&#160; ]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;[&#160; ]</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Item 1.02 &#160;&#160;&#160;&#160;Termination of a Material Definitive Agreement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;August 29, 2017, MacroGenics, Inc. (the &#8220;Company&#8221;) received written notice from Janssen Biotech, Inc. (&#8220;Janssen&#8221;), informing the Company of Janssen&#8217;s termination of a global collaboration and license agreement between Janssen and the Company relating to the development and commercialization of duvortuxizumab, a bispecific CD19 x CD3 DART&#174; molecule for the potential treatment of B-cell malignancies (the &#8220;Agreement&#8221;). In connection with this termination, Janssen plans to cease enrollment of the Phase 1 dose-escalation study of duvortuxizumab and the Company regained the worldwide rights to the molecule. Pursuant to the terms of the Agreement, unless the period is reduced by the Company, termination of the Agreement will become effective on February 25, 2018, which is 180 days after the effective date of Janssen&#8217;s notice of termination.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and Janssen are also parties to a separate collaboration and license agreement for MGD015, a preclinical DART molecule also known as JNJ-9383, that was entered into in May 2016 and is unaffected by termination of the duvortuxizumab Agreement. This product candidate incorporates the Company&#8217;s DART platform to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On&#160;August 31, 2017, the Company issued a press release announcing Janssen&#8217;s notice of termination of the Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01&#160;&#160;&#160;&#160;Financial Statements and Exhibits</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d) Exhibits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:9px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Press Release, dated August 31, 2017.</font></div><div style="line-height:144%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;padding-bottom:4px;padding-top:4px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURE</font></div><div style="line-height:144%;padding-bottom:4px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:7%;"></td><td style="width:44%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:&#160; August 31, 2017</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Jeffrey Peters</font></div><div style="padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jeffrey Peters</font></div><div style="padding-bottom:2px;padding-left:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President and Acting General Counsel</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1_pressreleasemg.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sCC5FAAC54CFE98F41C6439E74CC56860"></a></div><div><div style="line-height:120%;text-align:left;"><img src="mglogo.jpg" alt="mglogo.jpg" style="height:92px;width:157px;"></div></div><div><br></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">MacroGenics Announces Termination of Duvortuxizumab Collaboration and License Agreement with Janssen</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:14pt;padding-left:24px;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">Development of MGD015 (JNJ-9383) to continue by Janssen</font></div></td></tr></table><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">ROCKVILLE, MD, August 31, 2017 &#8211; MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that it had been notified by its partner, Janssen Biotech, Inc., that Janssen is terminating the collaboration and license agreement with MacroGenics relating to duvortuxizumab, a CD19 x CD3 DART&#174; molecule. Enrollment of the Phase 1 dose-escalation study of this molecule is being discontinued.</font></div><div style="line-height:138%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Janssen reaffirmed its commitment to MGD015, also known as JNJ-9383, a second DART molecule licensed from MacroGenics.  MGD015 is a preclinical program that targets CD3 and a non-disclosed cancer antigen expressed in hematological malignancies and lung cancer. Janssen has indicated that it anticipates initiating a first-in-human study with this molecule in 2018. </font></div><div style="line-height:138%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In the Phase 1 dose-escalation study of duvortuxizumab, multiple objective responses were observed in patients treated at various dosing levels tested. However, a number of patients experienced treatment-related neurotoxicity similar to that seen in patients treated with other CD19-targeted T-cell therapies. Given the recent advances in the highly competitive field for the treatment of B cell malignancies, the opportunity for development and commercialization has become less attractive.</font></div><div style="line-height:138%;padding-bottom:6px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;While this decision is disappointing, MacroGenics and its strategic partner, Janssen, continue to be fully committed to the DART platform and our ongoing collaboration on MGD015. Duvortuxizumab&#8217;s neurotoxicity profile is a CD19-targeting issue and has not been observed in our other DART clinical programs,&#8221; said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. &#8220;Given our large portfolio of product candidates currently being pursued, it is unlikely that we will continue development of this molecule at this time.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">About MacroGenics, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.MacroGenics.com. MacroGenics, the MacroGenics logo, DART and TRIDENT are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cautionary Note on Forward-Looking Statements</font></div><div style="line-height:138%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;"><img src="mglogo.jpg" alt="mglogo.jpg" style="height:92px;width:157px;"></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. </font></div><div style="line-height:138%;text-align:left;text-indent:281px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">###</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Contacts:</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jim Karrels, Senior Vice President, CFO</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;">MacroGenics, Inc.</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1-301-251-5172, </font><a style="font-family:inherit;font-size:11pt;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">info@</font></a><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">MacroGenics.com</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Karen Sharma, Senior Vice President</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:11pt;">MacDougall Biomedical Communications</font></div><div style="line-height:138%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1-781-235-3060, </font><a style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:underline;" href="#"><font style="font-family:inherit;font-size:11pt;color:#000000;text-decoration:underline;">ksharma@macbiocom.com</font></a></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mglogo.jpg
<TEXT>
begin 644 mglogo.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !D *P# 2(  A$! Q$!_\0
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MF?BX-()&$UM:R@_/W5B.R#LO?Z=?=Z**!A1112 **** "BBB@ HHHH ****
M"JDFDV4VI0Z@]K$U]"ACCN"HWJIZ@'_/4^M%%1*$9V4E?J5&3CL[%NBBBK)(
MYH8[F)HIHUEC;AD=00?J#7,WWPM\*7\C22:);1.W#-;;H"?^^"*** ,Z7X'^
M"IL>9H[R8Z;KVX./_(E:.E_"WPEH[!K;0++<.C31^:1[@OFBBF!U"JL:A5 5
D5& H& !3J**0!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
